EP1214079A4 - Arzneimittel zur behandlung von frakturen - Google Patents

Arzneimittel zur behandlung von frakturen

Info

Publication number
EP1214079A4
EP1214079A4 EP00952791A EP00952791A EP1214079A4 EP 1214079 A4 EP1214079 A4 EP 1214079A4 EP 00952791 A EP00952791 A EP 00952791A EP 00952791 A EP00952791 A EP 00952791A EP 1214079 A4 EP1214079 A4 EP 1214079A4
Authority
EP
European Patent Office
Prior art keywords
drug
treating fractures
fractures
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00952791A
Other languages
English (en)
French (fr)
Other versions
EP1214079A1 (de
Inventor
David G Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Royal Alexandra Hospital for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hospital for Children filed Critical Royal Alexandra Hospital for Children
Publication of EP1214079A1 publication Critical patent/EP1214079A1/de
Publication of EP1214079A4 publication Critical patent/EP1214079A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00952791A 1999-08-19 2000-08-17 Arzneimittel zur behandlung von frakturen Withdrawn EP1214079A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ232599 1999-08-19
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (2)

Publication Number Publication Date
EP1214079A1 EP1214079A1 (de) 2002-06-19
EP1214079A4 true EP1214079A4 (de) 2004-03-24

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00952791A Withdrawn EP1214079A4 (de) 1999-08-19 2000-08-17 Arzneimittel zur behandlung von frakturen

Country Status (16)

Country Link
EP (1) EP1214079A4 (de)
JP (1) JP2003507426A (de)
KR (1) KR20020027562A (de)
CN (1) CN100345548C (de)
AU (1) AUPQ232599A0 (de)
BR (1) BR0013416A (de)
CA (1) CA2381302A1 (de)
HK (1) HK1048441B (de)
HU (1) HUP0202396A3 (de)
IL (1) IL148166A0 (de)
NO (1) NO20020784D0 (de)
NZ (1) NZ517538A (de)
PL (1) PL353485A1 (de)
SK (1) SK2382002A3 (de)
WO (1) WO2001013922A1 (de)
ZA (1) ZA200202160B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233325C (zh) 2001-02-06 2005-12-28 罗亚尔·亚历山德拉儿童医院 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
US20040157798A1 (en) * 2001-04-03 2004-08-12 Little David Graham Drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
ES2379485T3 (es) * 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937A (zh) * 2020-11-18 2022-05-27 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
EP0600834A1 (de) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Verwendung von Methanbiphosphonsäurederivaten zur Herstellung eines Arzneimittels zur Behandlung von Knochenbrüchen
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
WO1995030421A1 (en) * 1994-05-04 1995-11-16 Ciba-Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011786A1 (en) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
EP0600834A1 (de) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Verwendung von Methanbiphosphonsäurederivaten zur Herstellung eines Arzneimittels zur Behandlung von Knochenbrüchen
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
WO1995030421A1 (en) * 1994-05-04 1995-11-16 Ciba-Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENISSEN H ET AL: "CERAMIC HYDROXYAPATITE IMPLANTS FOR THE RELEASE OF BIPHOSPHONATE", BONE AND MINERAL, SHANNON, IE, vol. 25, no. 2, 1994, pages 123 - 134, XP001015353 *
ECK J. ET AL: "Diagnosis and Treatment of Common Metabolic Spinal Disorders in the Geriatric Population", SOUTHERN MEDICAL JOURNAL, vol. 91, no. 12, 1998, pages 1089 - 1097, XP002906300 *
SABOKBAR A. ET AL: "Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption", ANNALS OF RHEUMATIC DISEASES, vol. 57, no. 10, 1998, pages 614 - 618, XP002953301, DOI: 10.1136/ard.57.10.614 *
See also references of WO0113922A1 *

Also Published As

Publication number Publication date
IL148166A0 (en) 2002-09-12
BR0013416A (pt) 2002-04-30
NO20020784L (no) 2002-02-18
HUP0202396A3 (en) 2005-02-28
EP1214079A1 (de) 2002-06-19
NO20020784D0 (no) 2002-02-18
CN100345548C (zh) 2007-10-31
HK1048441A1 (en) 2003-04-04
CA2381302A1 (en) 2001-03-01
SK2382002A3 (en) 2002-09-10
KR20020027562A (ko) 2002-04-13
WO2001013922A1 (en) 2001-03-01
HK1048441B (zh) 2008-02-22
JP2003507426A (ja) 2003-02-25
NZ517538A (en) 2003-07-25
ZA200202160B (en) 2003-08-27
PL353485A1 (en) 2003-11-17
CN1370071A (zh) 2002-09-18
AUPQ232599A0 (en) 1999-09-09
HUP0202396A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
HUP0200556A3 (en) Medicament for treating diabetes
HK1200316A1 (en) Therapeutic microfoams
IL138784A0 (en) Treatment for diabetes
PL350167A1 (en) Medicament for treating hypertension
GB9930570D0 (en) Therapy
GB9925136D0 (en) Novel treatment
GB9907243D0 (en) Therapy
IL148166A0 (en) Drug for treating fractures
PL349347A1 (en) Novel treatment
GB9900222D0 (en) Therapeutic compounds
HU9902296D0 (en) Pharmaceutical composition for treating caltification
GB0020261D0 (en) Therapeutic treatment
HUP0105469A3 (en) Therapeutic drugs comprising pyrroloazepines for treating intermittent claudication
GB9901505D0 (en) Therapeutic treatment
GB9918785D0 (en) Therapeutic treatment
HU9904711D0 (en) Set for fixation fractures
GB9919721D0 (en) Medical apparatus
GB9908993D0 (en) Treatment
GB9903558D0 (en) Medical treatment
GB9923343D0 (en) Treatment system
GB9924712D0 (en) Therapeutic method
AU142194S (en) Medical treatment apparatus
GB9927106D0 (en) Cancer treatment
GB9908176D0 (en) Cancer treatment
GB9909650D0 (en) Novel treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20020313

A4 Supplementary search report drawn up and despatched

Effective date: 20040205

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 19/00 B

Ipc: 7A 61K 31/663 A

Ipc: 7A 61K 31/675 B

17Q First examination report despatched

Effective date: 20041008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080903